Decreased Levels of Secretory Leucoprotease Inhibitor in the Pseudomonas-Infected Cystic Fibrosis Lung Are Due to Neutrophil Elastase Degradation1
暂无分享,去创建一个
Paul McNally | R. Levine | N. McElvaney | D. McAuley | J. Elborn | Sinéad Weldon | Rodney L Levine | A. Belaaouaj | Julien Wartelle | J Stuart Elborn | Noel G McElvaney | C. Taggart | Clifford C Taggart | Danny F McAuley | Abderrazzaq Belaaouaj | Julien Wartelle | P. McNally | Elborn | S. Weldon | Belaaouaj | Abderrazzaq
[1] N. McElvaney,et al. Delivery of rSLPI in a liposomal carrier for inhalation provides protection against cathepsin L degradation , 2009, Journal of microencapsulation.
[2] P. Sly,et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis , 2008, European Respiratory Journal.
[3] M. Butler,et al. Elafin, an Elastase-specific Inhibitor, Is Cleaved by Its Cognate Enzyme Neutrophil Elastase in Sputum from Individuals with Cystic Fibrosis* , 2008, Journal of Biological Chemistry.
[4] M. D'Andrea,et al. Cleaved SLPI, a novel biomarker of chymase activity , 2008, Biological chemistry.
[5] B. Fischer,et al. Proteases and cystic fibrosis. , 2008, The international journal of biochemistry & cell biology.
[6] Wiley Interscience,et al. Predictors of mortality in adults with cystic fibrosis , 2007, Pediatric pulmonology.
[7] T. Murray,et al. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients , 2007, Current opinion in pediatrics.
[8] J. Sallenave,et al. SLPI and elafin: one glove, many fingers. , 2006, Clinical science.
[9] N. McElvaney,et al. Secretory leucoprotease inhibitor binds to NF-κB binding sites in monocytes and inhibits p65 binding , 2005, The Journal of experimental medicine.
[10] A. Ding,et al. Suppression of macrophage responses to bacterial lipopolysaccharide (LPS) by secretory leukocyte protease inhibitor (SLPI) is independent of its anti-protease function. , 2005, Biochimica et biophysica acta.
[11] N. McElvaney,et al. Elastolytic proteases: inflammation resolution and dysregulation in chronic infective lung disease. , 2005, American journal of respiratory and critical care medicine.
[12] K. Rabe,et al. Transcriptional response of bronchial epithelial cells to Pseudomonas aeruginosa: identification of early mediators of host defense. , 2005, Physiological genomics.
[13] S. Doumas,et al. Anti-Inflammatory and Antimicrobial Roles of Secretory Leukocyte Protease Inhibitor , 2005, Infection and Immunity.
[14] J. Sallenave,et al. The antimicrobial antiproteinase elafin binds to lipopolysaccharide and modulates macrophage responses. , 2005, American journal of respiratory cell and molecular biology.
[15] N. McElvaney,et al. Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis. , 2004, The Journal of infectious diseases.
[16] N. McElvaney,et al. Secretory Leucoprotease Inhibitor Impairs Toll-Like Receptor 2- and 4-Mediated Responses in Monocytic Cells , 2004, Infection and Immunity.
[17] G. Slade,et al. Salivary Secretory Leukocyte Protease Inhibitor and Oral Candidiasis in Human Immunodeficiency Virus Type 1-Infected Persons , 2004, Infection and Immunity.
[18] R. Levine,et al. Inactivation of Human β-Defensins 2 and 3 by Elastolytic Cathepsins1 , 2003, The Journal of Immunology.
[19] J. Miyazaki,et al. Increased Susceptibility to LPS-induced Endotoxin Shock in Secretory Leukoprotease Inhibitor (SLPI)-deficient Mice , 2003, The Journal of experimental medicine.
[20] P. Lachmann,et al. Streptococcal Inhibitor of Complement Inhibits Two Additional Components of the Mucosal Innate Immune System: Secretory Leukocyte Proteinase Inhibitor and Lysozyme , 2002, Infection and Immunity.
[21] N. McElvaney,et al. Secretory Leucoprotease Inhibitor Prevents Lipopolysaccharide-induced IκBα Degradation without Affecting Phosphorylation or Ubiquitination* , 2002, The Journal of Biological Chemistry.
[22] R. Levine,et al. Cathepsin B, L, and S Cleave and Inactivate Secretory Leucoprotease Inhibitor* , 2001, The Journal of Biological Chemistry.
[23] R. Stockley,et al. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD , 2001, Thorax.
[24] K. Shirato,et al. Secretion and gene expression of secretory leukocyte protease inhibitor by human airway submucosal glands. , 2001, American journal of physiology. Lung cellular and molecular physiology.
[25] K. Rabe,et al. Regulation of secretory leukocyte proteinase inhibitor (SLPI) production by human bronchial epithelial cells: increase of cell-associated SLPI by neutrophil elastase. , 2000, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.
[26] J. Sallenave. The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteinases in inflammatory lung disease , 2000, Respiratory research.
[27] A. Lentsch,et al. Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor. , 2000, The American journal of pathology.
[28] Fenyu Jin,et al. Secretory Leukocyte Protease Inhibitor Interferes with Uptake of Lipopolysaccharide by Macrophages , 1999, Infection and Immunity.
[29] S. Ranganathan,et al. The whey acidic protein family: a new signature motif and three-dimensional structure by comparative modeling. , 1999, Journal of molecular graphics & modelling.
[30] A. Lentsch,et al. Inhibition of NF-κB Activation and Augmentation of IκBβ by Secretory Leukocyte Protease Inhibitor during Lung Inflammation , 1999 .
[31] D. Elashoff,et al. The bronchoalveolar lavage fluid of cystic fibrosis lung transplant recipients demonstrates increased interleukin-8 and elastase and decreased IL-10. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[32] E. Christophers,et al. Antileukoprotease in human skin: an antibiotic peptide constitutively produced by keratinocytes. , 1998, Biochemical and biophysical research communications.
[33] D. Radzioch,et al. Lipopolysaccharide-Related Stimuli Induce Expression of the Secretory Leukocyte Protease Inhibitor, a Macrophage-Derived Lipopolysaccharide Inhibitor , 1998, Infection and Immunity.
[34] M. Merten,et al. Pseudomonas aeruginosa lipopolysaccharide induces CF-like alteration of protein secretion by human tracheal gland cells. , 1997, Biochemical and biophysical research communications.
[35] P. Hiemstra,et al. Antileukoprotease: an endogenous protein in the innate mucosal defense against fungi. , 1997, The Journal of infectious diseases.
[36] D. Radzioch,et al. Secretory Leukocyte Protease Inhibitor: A Macrophage Product Induced by and Antagonistic to Bacterial Lipopolysaccharide , 1997, Cell.
[37] C. Vogelmeier,et al. Use of secretory leukoprotease inhibitor to augment lung antineutrophil elastase activity. , 1996, Chest.
[38] G. Steffens,et al. Antibacterial activity of antileukoprotease , 1996, Infection and immunity.
[39] D. Dripps,et al. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. , 1995, The Journal of clinical investigation.
[40] J. Hermans,et al. Pulmonary deposition and disappearance of aerosolised secretory leucocyte protease inhibitor. , 1995, Thorax.
[41] T. Suga,et al. Specific cleavage of secretory leukoprotease inhibitor by neutrophil elastase and saliva. , 1994, Biochemical pharmacology.
[42] B. Doebbeling,et al. Transferrin and lactoferrin undergo proteolytic cleavage in the Pseudomonas aeruginosa-infected lungs of patients with cystic fibrosis , 1993, Infection and immunity.
[43] J. Hoidal,et al. Interaction of secretory leukocyte protease inhibitor with proteinase-3. , 1993, American journal of respiratory cell and molecular biology.
[44] R. Crystal,et al. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. , 1992, The Journal of clinical investigation.
[45] R. Crystal,et al. Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. , 1991, The Journal of clinical investigation.
[46] K. Ohlsson,et al. The elimination of secretory leukocyte protease inhibitor (SLPI) after intravenous injection in dog and man. , 1990, Scandinavian journal of clinical and laboratory investigation.
[47] J. Dijkman,et al. Proteinase inhibitory activities of antileukoprotease are represented by its second COOH-terminal domain. , 1990, Biochimica et biophysica acta.
[48] F. Lottspeich,et al. The acid‐stable proteinase inhibitor of human mucous secretions (HUSI‐I, antileukoprotease) , 1986, FEBS letters.
[49] D. Johnson,et al. Inactivation of human bronchial mucosal proteinase inhibitor by Pseudomonas aeruginosa elastase. , 1982, The American review of respiratory disease.
[50] H. Tegner. Quantitation of human granulocyte protease inhibitors in non-purulent bronchial lavage fluids. , 1978, Acta oto-laryngologica.